1. Clinical Overview
Darbepoetin alfa is a recombinant erythropoiesis-stimulating agent (ESA) used to treat anemia. It is a hyperglycosylated analog of recombinant human erythropoietin (EPO), engineered to have a longer serum half-life, allowing for less frequent dosing compared to epoetin. It stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow.
| Onset | Duration | Bioavailability |
|---|---|---|
| Increased reticulocyte count is typically observed within 7-10 days. A significant rise in hemoglobin (Hb) is usually seen within 2-6 weeks of initiation. | The pharmacodynamic effect (erythropoiesis) persists for several days to weeks after a single dose, correlating with its long half-life. | Approximately 37% following subcutaneous (SC) administration. Bioavailability is lower and more variable compared to intravenous (IV) route. |
2. Mechanism of Action
Darbepoetin alfa binds to the erythropoietin receptor (EPOR) on the surface of erythroid progenitor cells (CFU-E and BFU-E) in the bone marrow. This binding activates the JAK2/STAT5 intracellular signaling pathway, promoting the proliferation, differentiation, and survival of these precursor cells, ultimately leading to increased production of mature red blood cells (RBCs).
3. Indications & Uses
- Anemia associated with Chronic Kidney Disease (CKD) in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) adult and pediatric patients (≥1 year).
- Anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy, where anemia is due to the myelosuppressive effect of chemotherapy.
4. Dosage & Administration
Adult Dosage: CKD: Initial SC/IV dose: 0.45 mcg/kg once weekly OR 0.75 mcg/kg once every 2 weeks. Adjust to maintain Hb ~10-12 g/dL, not to exceed 13 g/dL. Cancer Chemotherapy-Induced Anemia: Initial SC dose: 2.25 mcg/kg once weekly OR 500 mcg once every 3 weeks.
Administration: For subcutaneous use: Rotate injection sites (upper arm, abdomen, thigh). Do not shake. Inspect for particulate matter. Administer as a single injection. For intravenous use in dialysis patients: Administer via IV bolus at the end of dialysis session. Discard any unused portion.
5. Side Effects
Common side effects may include:
- Hypertension
- Headache
- Arthralgia
- Injection site pain/erythema
- Nausea
- Edema (peripheral)
- Fatigue
- Cough
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Heparin | Increased risk of thrombosis when used with ESAs in dialysis patients. | Moderate |
| ACE Inhibitors (e.g., Enalapril) | May blunt erythropoietic response. | Moderate |
| Angiotensin II Receptor Blockers (ARBs) | May blunt erythropoietic response. | Moderate |
| Immunosuppressants (e.g., Cyclosporine, Tacrolimus) | Theoretical increased risk of PRCA; clinical significance unclear. | Low |
7. Patient Counselling
- DO have your blood pressure checked regularly.
- DO report severe headaches, dizziness, or visual disturbances immediately.
- DO ensure adequate iron intake as prescribed.
- DO learn proper injection technique if self-administering.
- DONT skip regular blood tests (Hb, iron).
- DONT use if you have uncontrolled high blood pressure.
- DONT shake the vial/pre-filled syringe.
8. Toxicology & Storage
Overdose: Polycythemia (excessively high hemoglobin/hematocrit), hypertension, headache, dizziness, thrombosis (stroke, MI, DVT), hyperviscosity syndrome, and seizures.
Storage: Store at 2°C to 8°C (in a refrigerator). Do not freeze. Protect from light. Do not shake. The product may be stored at room temperature (not above 25°C) for a single period of up to 7 days. Once punctured, use immediately. Discard any unused portion. Keep out of reach of children.